KALA BIO, INC. Increase (Decrease) in Accounts Receivable
KALA BIO, INC. (KALA) reported Increase (Decrease) in Accounts Receivable of -$78.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2024-05-14
- KALA BIO, INC. increase (decrease) in accounts receivable for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- KALA BIO, INC. increase (decrease) in accounts receivable for the quarter ending 2023-09-30 was $0.00.
- KALA BIO, INC. increase (decrease) in accounts receivable for the quarter ending 2023-06-30 was $2.00K, a 99.75% decline year-over-year.
- KALA BIO, INC. increase (decrease) in accounts receivable for the quarter ending 2023-03-31 was -$80.00K.
- KALA BIO, INC. increase (decrease) in accounts receivable for fiscal 2023 was -$78.00K.
- KALA BIO, INC. increase (decrease) in accounts receivable for fiscal 2022 was -$15.14M, a 363.00% decline from fiscal 2021.
- KALA BIO, INC. increase (decrease) in accounts receivable for fiscal 2021 was $5.76M.
- KALA BIO, INC. increase (decrease) in accounts receivable for fiscal 2020 was -$1.96M, a 116.94% decline from fiscal 2019.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $2.00K derived: sum of 3 quarters · filed 2024-03-29 | -$78.00K 10-K · filed 2024-03-29 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.00K derived: sum of 2 quarters · filed 2023-11-13 | -$78.00K 10-Q · filed 2023-11-13 | -$73.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$78.00K 10-Q · filed 2023-08-04 | -$73.00K derived: sum of 3 quarters · filed 2024-05-14 | -$13.69M derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-03-31 | -$80.00K 10-Q · filed 2024-05-14 | -$75.00K derived: sum of 2 quarters · filed 2024-05-14 | -$13.70M derived: sum of 3 quarters · filed 2024-05-14 | -$12.89M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$13.62M derived: sum of 2 quarters · filed 2024-03-29 | -$12.81M derived: sum of 3 quarters · filed 2024-03-29 | -$15.14M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$13.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$12.82M derived: sum of 2 quarters · filed 2023-11-13 | -$15.14M 10-Q · filed 2023-11-13 | -$12.41M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $802.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$1.52M 10-Q · filed 2023-08-04 | $1.21M derived: sum of 3 quarters · filed 2023-08-04 | $1.98M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | -$2.33M 10-Q · filed 2023-05-09 | $405.00K derived: sum of 2 quarters · filed 2023-05-09 | $1.18M derived: sum of 3 quarters · filed 2023-05-09 | $829.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $3.50M derived: sum of 2 quarters · filed 2023-03-03 | $3.15M derived: sum of 3 quarters · filed 2023-03-03 | $5.76M 10-K · filed 2023-03-03 |
| 2021-09-30 | $771.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $424.00K derived: sum of 2 quarters · filed 2022-11-08 | $3.03M 10-Q · filed 2022-11-08 | $5.17M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$347.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.25M 10-Q · filed 2022-08-11 | $4.40M derived: sum of 3 quarters · filed 2022-08-11 | $7.58M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $2.60M 10-Q · filed 2022-05-16 | $4.75M derived: sum of 2 quarters · filed 2022-05-16 | $7.92M derived: sum of 3 quarters · filed 2022-05-16 | $7.41M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $5.32M derived: sum of 2 quarters · filed 2022-03-29 | $4.81M derived: sum of 3 quarters · filed 2022-03-29 | -$1.96M 10-K · filed 2022-03-29 |
| 2020-09-30 | $3.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $2.66M derived: sum of 2 quarters · filed 2021-11-15 | -$4.11M 10-Q · filed 2021-11-15 | $284.00K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | -$513.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$7.28M 10-Q · filed 2021-08-05 | -$2.89M derived: sum of 3 quarters · filed 2021-08-05 | -$1.37M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$6.77M 10-Q · filed 2021-05-05 | -$2.38M derived: sum of 2 quarters · filed 2021-05-05 | -$854.00K derived: sum of 3 quarters · filed 2021-05-05 | $120.00K derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $4.39M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $5.92M derived: sum of 2 quarters · filed 2021-02-25 | $6.89M derived: sum of 3 quarters · filed 2021-02-25 | $11.56M 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $2.50M derived: sum of 2 quarters · filed 2020-11-05 | $7.17M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $974.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $5.65M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $4.67M 10-Q · filed 2020-05-07 | |||
| 2015-12-31 | -$36.00K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |